Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S
19743.0k citationsA Fefer, E. Donnall Thomas et al.profile →
Bone-Marrow Transplantation
19751.3k citationsClift Ra, A Fefer et al.profile →
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation
1977662 citationsThomas Ed, CD Buckner et al.Bloodprofile →
Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia [published erratum appears in Blood 1989 Aug 15;74(3):1180]
1989468 citationsPL Weiden, Rainer Storb et al.Bloodprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of A Fefer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Fefer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Fefer more than expected).
This network shows the impact of papers produced by A Fefer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Fefer. The network helps show where A Fefer may publish in the future.
Co-authorship network of co-authors of A Fefer
This figure shows the co-authorship network connecting the top 25 collaborators of A Fefer.
A scholar is included among the top collaborators of A Fefer based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with A Fefer. A Fefer is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Benyunes, Mark, George Sale, Mary Beauchamp, et al.. (1996). Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.. PubMed. 17(3). 351–6.33 indexed citations
Benyunes, Mark, Carl M. Higuchi, Catherine Lindgren, et al.. (1995). Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.. PubMed. 16(2). 283–8.53 indexed citations
Golomb, Harvey M., A Fefer, David W. Golde, et al.. (1988). Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.. PubMed. 15(5 Suppl 5). 7–9.38 indexed citations
6.
Fefer, A, K M Sullivan, P L Weiden, et al.. (1987). Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation.. PubMed. 244. 401–8.71 indexed citations
Storb, Rainer, Thomas Ed, PL Weiden, et al.. (1978). One-hundred-ten patients with aplastic anemia (AA) treated by marrow transplantation in Seattle.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 10(1). 135–40.37 indexed citations
12.
Storb, R, PL Weiden, R. L. Prentice, et al.. (1977). Aplastic anemia (AA) treated by allogeneic marrow transplantation: the Seattle experience.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 9(1). 181–5.8 indexed citations
13.
Ed, Thomas, CD Buckner, M Banaji, et al.. (1977). One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 49(4). 511–533.662 indexed citations breakdown →
14.
Ed, Thomas, George Sale, Lerner Kg, et al.. (1976). Opportunistic infection and interstitial pneumonia following marrow transplantation for aplastic anemia and hematologic malignancy.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 8(4). 663–7.32 indexed citations
15.
Weiden, PL, Thomas Ed, Rainer Storb, et al.. (1976). Marrow transplantation in aplastic anemia and leukemia.. Comprehensive Therapy. 2(4). 57–62.1 indexed citations
16.
Ed, Thomas, et al.. (1976). Experience with second marrow transplants.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 4(4). 221–6.22 indexed citations
17.
Fefer, A, et al.. (1976). Leukaemia antigens. Stimulation of lymphocytes in mixed culture by cells from HL-A identical siblings. Clinical & Experimental Immunology. 23(2). 214.5 indexed citations
18.
Ed, Thomas, R Storb, PL Weiden, et al.. (1976). Recovery from aplastic anemia following attempted marrow transplantation.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 4(2). 97–102.86 indexed citations
19.
Weiden, PL, R Storb, Thomas Ed, et al.. (1976). Preceding transfusions and marrow graft rejection in dogs and man.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 8(4). 551–4.11 indexed citations
20.
Fefer, A. (1973). Treatment of a Moloney lymphoma with cyclophosphamide and H-2-incompatible spleen cells.. PubMed. 33(4). 641–4.16 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.